Matsuba R, et al. - The researchers examined the effect of tofogliflozin, a sodium glucose transporter 2 inhibitor, on peripheral glucose uptake in patients with type 2 diabetes mellitus (T2DM) by the hyperinsulinemic-euglycemic clamp method in a single-arm, open-label study. Among T2DM patients, tofogliflozin significantly improved insulin sensitivity and peripheral glucose uptake. These improvements were significantly associated with a reduction of body fat mass.